Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL28070942 | 0.98 | DRD2 (0.45) | DRD2DRD3HTR1A | |
| Sulfur Dioxide SCHEMBL28071143 | 0.93 | DRD2 (0.42) | DRD2DRD3HTR1A | |
| Guanidine SCHEMBL28415570 | 0.90 | DRD2 (0.43) | DRD2DRD3HTR1A | |
| SCHEMBL27547345 | 0.83 | DRD2 (0.41) | DRD2DRD3 | |
| SCHEMBL8143198 | 0.81 | DRD2 (0.41) | DRD2DRD3 | |
| SCHEMBL28648650 | 0.80 | DRD2 (0.50) | DRD2DRD3 | |
| SCHEMBL17224079 | 0.80 | — | — | |
| SCHEMBL17224077 | 0.80 | — | — | |
| SCHEMBL28289256 | 0.80 | — | — | |
| SCHEMBL28679348 | 0.79 | DRD2 (0.43) | DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102952086-B | Preparation method of 2-morpholinyl-substituted pyrimidine compounds | TIANJIN SCIPHARMACN LTD | 2013-08-28 | — | — | CN | claimed |
| CN-101553233-A | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-10-07 | — | — | CN | claimed |
| CN-101553232-A | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-10-07 | — | — | CN | claimed |
| CN-101516379-A | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-08-26 | — | — | CN | claimed |
| WO-2025133334-A1 | NOVEL VDAC1 INHIBITORS | ABARCEO PHARMA AB (SE) | 2025-06-26 | — | — | WO | disclosed |
| CN-111303048-B | Pyrimidine guanidine compound, and preparation method and application thereof | 沈阳农业大学 | 2023-05-26 | — | — | CN | disclosed |
| CN-110461842-A | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL | 2019-11-15 | — | — | CN | disclosed |
| CN-107108672-B | Condensed five rings imdazole derivatives | UCB生物制药私人有限公司 | 2019-11-08 | — | — | CN | disclosed |
| CN-105814043-B | Triazolopyridine derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2019-05-17 | — | — | CN | disclosed |
| CN-105814049-B | Fused tricyclic imdazole derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2019-03-12 | — | — | CN | disclosed |
| CN-109219608-A | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB生物制药私人有限公司 | 2019-01-15 | — | — | CN | disclosed |
| CN-109219609-A | FUSED HEXACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB生物制药私人有限公司 | 2019-01-15 | — | — | CN | disclosed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040053937-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. | 2004-03-18 | — | — | US | disclosed |
| US-20040048873-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP., A DELAWARE CORPORATIO | 2004-03-11 | — | — | US | disclosed |
| US-6693097-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. | 2004-02-17 | — | — | US | disclosed |
| US-20040024206-A1 | Pyrimidine compounds | MADRIGAL PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6660733-B2 | Induce immunology response | SYNTA PHARMACEUTICALS CORP. | 2003-12-09 | — | — | US | disclosed |
| US-20030139403-A1 | Pyrimidine compounds | SHIONOGI BIORESEARCH CORP. | 2003-07-24 | — | — | US | disclosed |
| US-20030114446-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053937-A1 | Pyrimidine compounds | CCNO, CNR1, CBR1 | DRD2 567/4885DRD3 828/4885HTR1A 645/4885 |
| US-20030139403-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | DRD2 75/4885DRD3 124/4885HTR1A 1705/4885 |
| US-20030114446-A1 | Pyrimidine compounds | CCNO, CNR1, CBR1 | DRD2 570/4885DRD3 778/4885HTR1A 686/4885 |
| US-20040024206-A1 | Pyrimidine compounds | CBR1, CCR4, CNR1 | DRD2 524/4885DRD3 617/4885HTR1A 2249/4885 |
| US-20040048873-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | DRD2 68/4885DRD3 101/4885HTR1A 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.